SCHEMBL23478524

SCHEMBL23478524

CC(C)c1ccc2c(N)coc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.44
▸ GAA P10253 3/20 0.44
▸ HTT P42858 2/20 0.44
▸ ALOX12 P18054 1/20 0.44
▸ HIF1A Q16665 1/20 0.44
▸ PTPN1 P18031 1/20 0.43
▸ TBK1 Q9UHD2 4/20 0.39
▸ IKBKE Q14164 2/20 0.37
▸ NPC1 O15118 4/20 0.36
▸ RAB9A P51151 4/20 0.36
▸ MAPT P10636 4/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ TP53 P04637 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ KMT2A Q03164 2/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ KIF11 P52732 1/20 0.36
▸ LMNA P02545 2/20 0.34
▸ SMN1; SMN2 Q16637 2/20 0.34
▸ SCN4A P35499 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17615540 0.79 PTPN1 (0.47) ALDH1A1GAAHTTALOX12HIF1A
SCHEMBL10216166 0.79 PTPN1 (0.44) ALDH1A1GAAHTTALOX12HIF1A
SCHEMBL20409266 0.78 TRPA1 (0.46) ALDH1A1GAAHTTALOX12HIF1A
SCHEMBL22868110 0.75 SMN1; SMN2 (0.49) ALDH1A1GAAHTTNPC1RAB9A
SCHEMBL8629117 0.74 ALDH1A1 (0.44) ALDH1A1GAANPC1RAB9AMAPT
SCHEMBL22672437 0.73 TBK1 (0.48) GAAPTPN1TBK1IKBKENPC1
SCHEMBL22185375 0.73 PIN1 (0.59) ALDH1A1GAAHTTHIF1APTPN1
SCHEMBL2706167 0.71 BCHE (0.45) ALDH1A1GAAHTTALOX12HIF1A
SCHEMBL23478670 0.70 ALDH1A1 (0.44) ALDH1A1GAANPC1RAB9AMAPT
SCHEMBL4418715 0.70 PTK2 (0.32) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 — — US disclosed
US-11807641-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2023-11-07 — — US disclosed
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-17 — — US disclosed
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE OMEROS CORPORATION 2021-06-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210171531-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4709/4885GAA 1678/4885HTT 2319/4885
US-11807641-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ALDH1A1 4709/4885GAA 1678/4885HTT 2319/4885
US-20210179612-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4709/4885GAA 1678/4885HTT 2319/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 ALDH1A1 4709/4885GAA 1678/4885HTT 2319/4885
US-20210171461-A1 MASP-2 INHIBITORS AND METHODS OF USE MASP2, METAP2, SPINT2 ALDH1A1 4709/4885GAA 1678/4885HTT 2319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback